ARDELYX, INC. Unrealized Gain (Loss) on Derivatives
ARDELYX, INC. (ARDX) reported Unrealized Gain (Loss) on Derivatives of $407.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2021-03-08
- ARDELYX, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-12-31 was $406.71M, a 6.67% decline year-over-year.
- ARDELYX, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-09-30 was $138.00K, a 25.41% decline year-over-year.
- ARDELYX, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-06-30 was $70.00K, a 191.67% increase year-over-year.
- ARDELYX, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-03-31 was $82.00K, a 121.62% increase year-over-year.
- ARDELYX, INC. unrealized gain (loss) on derivatives for fiscal 2020 was $407.00M, a 6.65% decline from fiscal 2019.
- ARDELYX, INC. unrealized gain (loss) on derivatives for fiscal 2019 was $436.00M, a 18.20% decline from fiscal 2018.
- ARDELYX, INC. unrealized gain (loss) on derivatives for fiscal 2018 was $533.00M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2020-12-31 | $406.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $406.85M derived: sum of 2 quarters · filed 2021-03-08 | $406.92M derived: sum of 3 quarters · filed 2021-03-08 | $407.00M 10-K · filed 2021-03-08 |
| 2020-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $208.00K derived: sum of 2 quarters · filed 2020-11-05 | $290.00K 10-Q · filed 2020-11-05 | $436.04M derived: sum of 4 quarters · filed 2021-03-08 |
| 2020-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $152.00K 10-Q · filed 2020-08-06 | $435.91M derived: sum of 3 quarters · filed 2021-03-08 | $436.09M derived: sum of 4 quarters · filed 2021-03-08 |
| 2020-03-31 | $82.00K 10-Q · filed 2020-05-07 | $435.84M derived: sum of 2 quarters · filed 2021-03-08 | $436.02M derived: sum of 3 quarters · filed 2021-03-08 | $436.05M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-12-31 | $435.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $435.94M derived: sum of 2 quarters · filed 2021-03-08 | $435.96M derived: sum of 3 quarters · filed 2021-03-08 | $436.00M 10-K · filed 2021-03-08 |
| 2019-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $209.00K derived: sum of 2 quarters · filed 2020-11-05 | $246.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $61.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $37.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $533.00M 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |